Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this research letter from the British Journal of Dermatology, the authors explore the use of topical tofacitinib to treat alopecia areata affecting facial hair, but specific results are not reported in the abstract.

This study observed that some children and young adults with alopecia areata experienced flares during long-term tofacitinib treatment, despite initial successful hair regrowth.

This study presents the first documented case of dramatic hair regrowth in a systemic lupus erythematosus patient with refractory alopecia following tofacitinib therapy, suggesting a potential new application for JAK inhibitors in difficult-to-treat cutaneous SLE manifestations.

This study identified overlapping genetic susceptibility loci in both alopecia areata and inflammatory bowel disease, specifically with Crohn's disease and ulcerative colitis.

This case report highlights a 33-year-old female with systemic lupus erythematosus and refractory alopecia who experienced significant hair regrowth after treatment with tofacitinib, maintained even after glucocorticoid tapering over two years.

This report describes a case where the JAK inhibitor tofacitinib led to hair regrowth in a patient with alopecia totalis but also worsened facial acne, highlighting a unique adverse effect.

In this report, a female patient with ulcerative colitis, alopecia areata, and pyoderma gangrenosum showed improvement in all three conditions after being treated with tofacitinib.

In this case report, a 39-year-old woman's symptoms from dermatomyositis–systemic lupus erythematosus overlap syndrome improved only after she was treated with tofacitinib.

No results are provided in this article as it lacks an available abstract, making it unclear what effects apremilast and tofacitinib have in a humanized mouse model of alopecia areata.

This case report documented successful full hair regrowth in an 8-year-old with alopecia universalis after oral tofacitinib treatment, but mild headaches led to discontinuation.

This study demonstrated the potential of a methodology combining ToF-SIMS and AFM to effectively analyze human hair structure and identify cosmetic residues, which can aid the cosmetic industry in product development.

In this retrospective analysis, the authors reported that off-label tofacitinib treatment in 35 alopecia areata patients demonstrated safety, with no serious adverse events, and effectiveness, with 83.9% showing significant scalp regrowth and 32.3% achieving near total or total regrowth.

In this study, patients with specific skin and scalp conditions, including eczematous lesions, showed significant improvement after two weeks of oral tofacitinib treatment, as evidenced by changes in the trunk lesions.

Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.

This article is a letter to the editor discussing potential therapeutic synergy between a wig-fixing device and tofacitinib for treating alopecia areata but reports no new clinical results.

This study reports significant hair regrowth in 11 patients with severe alopecia areata following longstanding treatment with oral tofacitinib and also highlights successful treatment using topical tofacitinib cream in one case.

This study found that monounsaturated oils like olive oil penetrate hair fibers effectively, whereas polyunsaturated oils typically do not penetrate beyond the cuticle.

Many patients with alopecia areata relapse after stopping tofacitinib.

In this case report, researchers identified a potential adverse skin reaction, called SDRIFE or Baboon syndrome, caused by the drug tofacitinib in a 19-year-old woman being treated for alopecia subtotalis, leading the authors to recommend discontinuation of the drug.

This source discusses that while oral JAK inhibitors are used for treating lichen planopilaris and frontal fibrosing alopecia, they carry significant risk of adverse events; two cases showed promising results using tofacitinib cream as a safer topical alternative.

In this study, researchers observed that phospholipid-calcium carbonate hybrid nanoparticles effectively delivered Tofacitinib citrate topically, which significantly inhibited hair follicle apoptosis and promoted hair growth in a mouse model of chemotherapy-induced alopecia, compared to a traditional Tofacitinib solution.

This case report suggests that JAK inhibitors like tofacitinib may effectively treat alopecia in patients with complex cases involving both rheumatological and dermatological conditions.

In this open-label trial, tofacitinib showed dramatic clinical responses in most patients with moderate-to-severe alopecia areata, supporting further research into JAK inhibitors for this condition.

This study investigated the penetration of a low-molecular-weight cationic conditioning compound into the hair cortex and suggests it may improve hair's fatigue resistance.

This case report describes two patients with ulcerative colitis and alopecia areata who did not respond to various treatments but achieved remission and improved hair growth after starting tofacitinib.

This retrospective study observed that switching from tofacitinib to baricitinib improved hair growth in patients with alopecia areata, particularly for previous non-responders, and noted fewer side effects with baricitinib.

This study found that Janus Kinase inhibitors, tofacitinib and baricitinib, showed effectiveness and safety in treating severe alopecia areata in a real-world setting, with optimal tolerability noted in younger individuals.

This study reports that tofacitinib, a JAK 1/3 inhibitor, showed significant improvement in a patient with co-occurring severe alopecia totalis and lichen planus hypertrophicus, conditions that are typically resistant to treatment.

This study involving 126 patients found that tofacitinib has high effectiveness and an acceptable safety profile for treating alopecia areata, with a 33.8% complete response rate at 24 weeks and sex as an independent risk factor for outcomes.

In this study, tofacitinib showed a mixed response in treating refractory alopecia areata, with some patients experiencing complete or partial hair regrowth and others showing no response, particularly those with alopecia universalis.